Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Sopharma AD-Sofia's cash receipts from operating activities for the
three
months ended in Jun. 2026 was €417 Mil.
2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.
Sopharma AD-Sofia's cash payments for the
three
months ended in Jun. 2026 was €-386 Mil.
3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.
Sopharma AD-Sofia's cash payments for the
three
months ended in Jun. 2026 was €0 Mil.
4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.
Sopharma AD-Sofia's cash payments for the
three
months ended in Jun. 2026 was €0 Mil.
5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.
Sopharma AD-Sofia's cash payments for the
three
months ended in Jun. 2026 was €-2 Mil.
6. Interest Received:
It represents interest received by the company in the direct cash flow method.
Sopharma AD-Sofia's cash payments for the
three
months ended in Jun. 2026 was €0 Mil.
7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.
Sopharma AD-Sofia's cash payments for the
three
months ended in Jun. 2026 was €-20 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).
Sopharma AD-Sofia's cash flow from others for the
three
months ended in Jun. 2026 was €0 Mil.
Sopharma AD-Sofia Cash Flow from Operations Related Terms
Sopharma AD-Sofia Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Sopharma AD-Sofia's Cash Flow from Operations for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of €61 Mil mean?
Sopharma AD-Sofia (FRA:3JR) has a Cash Flow from Operations of €61 Mil as of Jun. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Cash Flow from Operations too high?
Sopharma AD-Sofia's current Cash Flow from Operations is €61 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Cash Flow from Operations compare to MCK and COR?
Sopharma AD-Sofia's Cash Flow from Operations of €61 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Medical Distribution company?
A good Cash Flow from Operations depends on the Medical Distribution industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Cash Flow from Operations is €61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Sopharma AD-Sofia (FRA:3JR) has a current Cash Flow from Operations of €61 Mil. The stock's GF Value™ is €2.06, compared to a current price of €2.11 — trading 2.4% above its estimated fair value. The current Cash Flow from Operations is €61 Mil. Sopharma AD-Sofia's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current Cash Flow from Operations is €61 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued.
The current stock price of €2.11 is trading 2.4% above its estimated GF Value™ of €2.06.
Key valuation signals for FRA:3JR:
Cash Flow from Operations: €61 Mil
GF Value™: €2.06 vs. price of €2.11 (2.4% above fair value)
No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
55GF Score
Get the complete analysis for FRA:3JR
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3JR has been successfully added to your 
